H.C. Wainwright Assigned a Buy Rating to Alliqua
By George Macdonald
In a report published on May 15, Swayampakula Ramakanth from H.C. Wainwright Assigned a Buy rating to Alliqua (NASDAQ: ALQA), with a price target of $11. The company’s shares closed last Friday at $4.48.
Alliqua has an analyst consensus of Strong Buy, with a price target consensus of $8.
The company has a one year high of $7.20 and a one year low of $3.70. Currently, Alliqua has an average volume of 90.85k.
According to TipRanks, Ramakanth is a 3-star analyst with an average return of 4.6% and a 28.1% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as IntelGenx Technologies, Sorrento Therapeutics, and Aldeyra Therapeutics.
Alliqua BioMedical Inc is a biomedical company providing wound care solutions. It is also engaged in contract manufacturing.
